Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients

Neuropsychobiology

Volumn 53, Issue 4, 2006, Pages 186-195

  Kato, Masaki ^a   Fukuda, Tsuyoshi ^b   Wakeno, Masataka ^a   Fukuda, Kazuhiro ^b   Okugawa, Gaku ^a   Ikenaga, Yuka ^b   Yamashita, Megumi ^b   Takekita, Yoshiteru ^a   Nobuhara, Kenji ^a   Azuma, Junichi ^b   Kinoshita, Toshihiko ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

5 Hydroxytryptamine type 2A; 5 Hydroxytryptamine type 3A; 5 Hydroxytryptamine type 3B; Depression, major recurrent; Selective serotonin reuptake inhibitors; Serotonin transporter genes

Indexed keywords

FLUVOXAMINE; GENOMIC DNA; PAROXETINE; SEROTONIN 2A RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; GENE; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HEADACHE; HTR2A GENE; HTR3A GENE; HTR3B GENE; HUMAN; HUMAN CELL; JAPAN; LEUKOCYTE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; PRIORITY JOURNAL; PROMOTER REGION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SEXUAL DYSFUNCTION; TANDEM MASS SPECTROMETRY;

ADULT; ANTIDEPRESSIVE AGENTS; CHI-SQUARE DISTRIBUTION; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUVOXAMINE; HUMANS; JAPAN; MALE; MIDDLE AGED; PAROXETINE; RECEPTORS, SEROTONIN, 5-HT2; RETROSPECTIVE STUDIES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEVERITY OF ILLNESS INDEX;

EID: 33747396949     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094727     Document Type: Article

References (53)

1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105.
2. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, Vieta E, Moller HJ: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. I. Treatment of bipolar depression. World J Biol Psychiatry 2002;3:115-124.
3. Fava M, Davidson KG: Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200.
4. Jonson AM: The comparative pharmacological properties of selective serotonin re-uptake inhibitors in animals; in Feigner JP, Boyer WF (eds): Perspectives in Psychiatry: Selective Serotonin Re-Uptake Inhibitors. Chichester, Wiley, 1991, vol 1, pp 37-70.
5. Hiemke C, Hartter S: Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000;85:11-28.
6. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmoller J: CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001;104:173-192.
7. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003;305:197-204.
8. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP: Allelic variation of human serotonin transporter gene expression. J Neurochem 1996;66:2621-2624.
9. Kato M, Ikenaga Y, Wakeno M, Okugawa G, Nobuhara K, Fukuda T, Fukuda K, Azuma J, Kinoshita T: Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol 2005;20:151-156.
10. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998;3:508-511.
11. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000;23:587-590.
12. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E: Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000;20:105-107.
13. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ: Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002;7:1115-1119.
14. Hong CJ, Chen TJ, Yu YW, Tsai SJ: Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 2006;6:27-33.
15. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, Carroll BJ: Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000;11:215-219.
16. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K: Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:383-386.
17. Serretti A, Artioli P: The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J 2004;4:233-244.
18. Landolt HP, Meier V, Burgess HJ, Finelli LA, Cattelin F, Achermann P, Borbely AA: Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology 1999;21:455-466.
19. Pullar IA, Carney SL, Colvin EM, Lucaites VL, Nelson DL, Wedley S: LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant nefazodone. Eur J Pharmacol 2000;407:39-46.
20. Janssen P, Prins NH, Meulemans AL, Lefebvre RA: Pharmacological characterization of the 5-HT receptors mediating contraction and relaxation of canine isolated proximal stomach smooth muscle. Br J Pharmacol 2002;136:321-329.
21. Spurlock G, Heils A, Holmans P, Williams J, D'Souza UM, Cardno A, Murphy KC, Jones L, Buckland PR, McGuffin P, Lesch KP, Owen MJ: A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry 1998;3:42-49.
22. Cusin C, Serretti A, Zanardi R, Lattuada E, Rossini D, Lilli R, Lorenzi C, Smeraldi E: Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int J Neuropsychopharmacol 2002;5:27-35.
23. Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P, Rupprecht R, Bondy B: Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett 2001;303:119-122.
24. Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF: Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003;160:1830-1835.
25. Suzuki Y, Sawamura K, Someya T: Polymorphisms in the 5-hydroxytryptamine 2A receptor and cytochrome P450 2D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. Neuropsychopharmacology 2006;31:825-831.
26. Choi MJ, Kang RH, Ham BJ, Jeong HY, Lee MS: Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology 2005;52:155-162.
27. Miyake A, Mochizuki S, Takemoto Y, Akuzawa S: Molecular cloning of human 5-hydroxytryptamine 3 receptor: heterogeneity in distribution and function among species. Mol Pharmacol 1995;48:407-416.
28. Belelli D, Balcarek JM, Hope AG, Peters JA, Lambert JJ, Blackburn TP: Cloning and functional expression of a human 5-hydroxytryptamine type 3AS receptor subunit. Mol Pharmacol 1995;48:1054-1062.
29. Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG, Kirkness EF: The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 1999;397:359-363.
30. 3B receptor subunit. J Biol Chem 1999;274:30799-30810.
31. Bruss M, Gothert M, Hayer M, Bonisch H: Molecular cloning of alternatively spliced human 5-HT3 receptor cDNAs. Ann NY Acad Sci 1998;861:234-235.
32. Tremblay PB, Kaiser R, Sezer O, Rosler N, Schelenz C, Possinger K, Roots I, Brockmoller J: Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003;21:2147-2155.
33. Niesler B, Flohr T, Nothen MM, Fischer C, Rietschel M, Franzek E, Albus M, Propping P, Rappold GA: Association between the 5′-UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder. Pharmacogenetics 2001;11:471-475.
34. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
35. Seretti A, Cusin C, Lattuada E, Di Bella D, Catalano M, Smeraldi E: Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders. Mol Psychiatry 1999;4:280-283.
36. Lucca A, Lucini V, Catalano M, Alfano M, Smeraldi E: Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor. Neuropsychobiology 1994;29:108-111.
37. Deckert J, Catalano M, Heils A, Di Bella D, Friess F, Politi E, Franke P, Nothen MM, Maier W, Bellodi L, Lesch KP: Functional promoter polymorphism of the human serotonin transporter: lack of association with panic disorder. Psychiatr Genet 1997;7:45-47.
38. Tot S, Erdal ME, Yazici K, Yazici AE, Metin O: T102C and -1438 G/A polymorphisms of the 5-HT2A receptor gene in Turkish patients with obsessive-compulsive disorder. Eur Psychiatry 2003;18:249-254.
39. Melke J, Westberg L, Nilsson S, Landen M, Soderstrom H, Baghaei F, Rosmond R, Holm G, Bjorntorp P, Nilsson LG, Adolfsson R, Eriksson E: A polymorphism in the serotonin receptor 3A (HTR3A) gene and its association with harm avoidance in women. Arch Gen Psychiatry 2003;60:1017-1023.
40. Kunugi H, Hattori M, Kato T, Tatsumi M, Sakai T, Sasaki T, Hirose T, Nanko S: Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry 1997;2:457-462.
41. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-1531.
42. Parsons MJ, D'Souza UM, Arranz MJ, Kerwin RW, Makoff AJ: The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry 2004;56:406-410.
43. 2A receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 2002;46:136-140.
44. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP: Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004;9:879-889.
45. Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, Naito S, Shimizu T, Itoh K, Inoue K, Suzuki T, Nemeroff CB: Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004;161:1575-1580.
46. Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Suzuki T, Ohkubo T: Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. Neuropsychobiology 2003;48:10-13.
47. 3H]granisetron-labelled 5-HT3 receptor in the human forebrain. Neuropharmacology 1993;32:1325-1331.
48. Frank B, Niesler B, Nothen MM, Neidt H, Propping P, Bondy B, Rietschel M, Maier W, Albus M, Rappold G: Investigation of the human serotonin receptor gene HTR3B in bipolar affective and schizophrenic patients. Am J Med Genet B Neuropsychiatr Genet 2004;131:1-5.
49. Ansseau M, Garbriels A, Loyens J, Bartholome F, Evrard J, De Nayer A, Linhart R, Wirtz J, Btuynooghe F, Surinx K, Clarysse H, Marganne R, Papart P: Controlled comparison of paroxetine and fluvoxamine in major depression. Hum Psychopharmacol 1994;9:329-336.
50. Kiev A, Feiger A: A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 1997;58:146-152.
51. Horton RW, De Paermentier F, Lowther S, Lawrence KM, Compton MR, Tulloch IF: The interaction of antidepressant drugs with neurotransmitter receptor binding sites and 5-HT uptake sites in human brain in vitro. Eur Neuropsychopharmacol 1993;3:344-345.
52. Ali I: Long-term treatment with antidepressant in primary care. Psychiatr Bull 1998;22:15-19.
53. Pritchard JK, Rosenberg NA: Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999;65:220-228.